Drugs / Pneumococcal vaccine
Pneumococcal vaccine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01339000 | Apr 2011 → Apr 2016 | breast cancer, colon carcinoma, urinary bladder cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00721396 | Aug 2008 → Jul 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00327522 | Jun 2006 → ? | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00338351 | Apr → Oct 2006 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00323557 | Jun 2004 → May 2011 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07242092 | Jun 2026 → Dec 2027 expected | rheumatic disorder | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT01597492 | May 2012 → Sep 2015 | systemic lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00239694 | Apr 2001 → Aug 2012 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04515147 Comparator | Sep 2020 → Feb 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
| Phase 3 | NCT01411241 Background | Jul 2011 → Feb 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Press releases naming this drug 10 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal vaccine | “The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).” NCT01597492 ↗ |
| Known as | 11PCV Vaccine | “An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.” NCT00327522 ↗ |
| Known as | 20-valent Pneumococcal Conjugate Vaccine (PCV20) | “20-valent Pneumococcal Conjugate Vaccine (PCV20)” NCT07242092 ↗ |
| Known as | PCV20 | “All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0).” NCT07242092 ↗ |
| Known as | Prevnar 20 | “All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0).” NCT07242092 ↗ |
| Modality | Vaccine | “One time preventative vaccine” NCT00239694 ↗ |
| Route | Subcutaneous | “Subcutaneously on Day 0” NCT00323557 ↗ |